Decision Diagnostics Corp (DECN)

[BIOCHEMUP]

It appears to the Securities and Exchange Commission that the public interest and the protection of investors require a suspension in the trading of the securities of Decision Diagnostics Corp. (“DECN” or “the Company”) (CIK No. 0001144225) because of questions regarding the accuracy and adequacy of information in the marketplace since at least March 3, 2020.Those questions relate to DECN’s press releases, among other things, (i) claiming to have “technology perfected” to allow it to manufacture and sell a COVID-19 test kit that would provide results “in 15 seconds, based on a small finger prick blood sample,” and (ii) issuing sales forecasts that up to 525 million COVID 19 test kits would be sold in the first year of production. The Company’s common stock is quoted on OTC Link (previously Pink Sheets), operated by OTC Markets Group Inc., under the symbol DECN.

Exaggerated and/or false claims.